Endonovo Therapeutics (ENDV)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Aug 14, 2024 03:35 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Endonovo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 3 | 3 | 2 | 3 | 4 |
Income After Depreciation & Amortization | -3 | -3 | -2 | -3 | -4 |
Non-Operating Income | 11 | -14 | 0 | 5 | -7 |
Interest Expense | 1 | 1 | 1 | 2 | 6 |
Pretax Income | 7 | -18 | -3 | 0 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 7 | -18 | -3 | 0 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 7 | -18 | -3 | 0 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -2 | -3 | -1 | -2 | -1 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 3 |
Income After Depreciation & Amortization | -3 | -3 | -2 | -3 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 12.22 | 0.70 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | -0.03 | -24.83 |
Diluted Net EPS (GAAP) | 0.01 | -0.13 | -0.05 | -0.03 | -24.83 |
Fiscal Year end for Endonovo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 0.01 | 0.00 | 0.05 |
Cost Of Goods | NA | NA | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | NA | 0.00 | 0.00 | 0.05 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.79 | 0.47 | 1.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -0.79 | -0.47 | -1.13 |
Non-Operating Income | NA | NA | -0.44 | -0.01 | 3.51 |
Interest Expense | NA | NA | 0.37 | 0.29 | 0.31 |
Pretax Income | NA | NA | -1.60 | -0.77 | 2.06 |
Income Taxes | NA | NA | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | -1.60 | -0.77 | 2.06 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | -1.60 | -0.77 | 2.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 1,350.81 | 1,350.74 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | 0.00 | -0.01 |
Diluted Net EPS (GAAP) | NA | NA | 0.02 | 0.00 | -0.01 |